Eligo Bioscience

Institut Pasteur

Antoine Decrulle

Xavier Duportet

Jesus Fernandez Rodriguez

Aymeric Leveau

Aurélie Mathieu

Inès Canadas Blasco

David Bikard

Cristina Del Carmen Gil-Cruz

Burkhard Ludewig

Christian Ivan Pérez-Shibayama

Andreas Brodel

Thibault Carlier

Igor Stzepourginski

The invention relates tocarrying DNA vectors with aphage packaging signal and a gene of interest. The invention encompasses aproducer cell carrying DNA vectors, with aphage packaging signal and a gene of interest, for the production of phage-derived particles that can robustly transducereceiver cell allowing transgene expression. The invention encompassesphage-derived particles carrying these vectors,containing these vectors or modified by transduction of these phage-derived particles, and methods of using these phage-derived particles.

Phage-derived particles for in situ delivery of DNA payload into C. acnes population

The invention relates tostrains carrying DNA vectors for the production of recombinantphages. The invention encompasses aproducer cell carrying DNA vectors, with a template for recombination withphage genome leading to the insertion of a gene of interest, for the production of recombinant phages that can lead to the transgene expression intoinfected by the recombinant phage. The invention encompasses,strains containing these vectors,recombinant phages and methods of using these recombinant phages.

recombinant phages encoding a human protein

A method for the cosmetic caring of the skin and/or mucosa, comprising applying a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, wherein the postbiotic is preferably a bacterial lysate preferably obtained from bacteria heterologously expressing the at least one bacteriocin and/or endolysin and wherein the postbiotic and the at least one bacteriocin and/or endolysin have a synergistic effect in the cosmetic caring method.

Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins

Phage-derived particles for in situ delivery of DNA payload intopopulation

The present invention relates to the delivery of a payload by bacterial delivery vehicle, i.e. the encapsulation and the delivery of a single plasmid by different bacterial virus particles. More specifically, the present invention concerns a pharmaceutical composition comprising a payload packaged in at least two different bacterial delivery vehicles and a method of production thereof.

Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof

The present invention concerns a production bacterial cell for producing lytic phage particles or lytic phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural genes and at least one phage DNA packaging genes, said phage structural gene(s) and phage DNA packaging gene(s) being derived from a lytic bacteriophage, wherein the expression of at least one of said phage structural genes and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by an induction mechanism.

Production of lytic phages

The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than 100, preferably no more than 10, restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.

Optimized vector for delivery in microbial populations

The present invention concerns a production bacterial cell for producing phage particles or phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural gene(s) and at least one phage DNA packaging gene(s), said phage structural gene(s) and phage DNA packaging gene(s) being derived from a first type of bacteriophage,

Production bacterial cells and use thereof in production methods

The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than (100), preferably no more than (10), restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.

Recombinantphages comprising transgenes

The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use as a medicament, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the therapeutic treatment.

Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins

The present invention concerns a production bacterial cell for producing lytic phage particles or lytic phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural genes and at least one phage DNA packaging genes, said phage structural gene(s) and phage DNA packaging gene(s) being derived from a lytic bacteriophage,

The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.

Growing community of inventors

Paris, France

Antoine Decrulle